Literature DB >> 291484

Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report.

E S Baum, P Gaynon, L Greenberg, W Krivit, D Hammond.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 291484

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  8 in total

Review 1.  Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors.

Authors:  Daniel M Green; Larry E Kun; Katherine K Matthay; Anna T Meadows; William H Meyer; Paul A Meyers; Sheri L Spunt; Leslie L Robison; Melissa M Hudson
Journal:  Pediatr Blood Cancer       Date:  2013-02-15       Impact factor: 3.167

2.  Intolerance to cisplatin--a case report.

Authors:  G E Umbach; H von Matthiessen; G Wirth; G Goerz
Journal:  Arch Gynecol       Date:  1985

3.  Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.

Authors:  S S Bielack; R Erttmann; G Looft; C Purfürst; G Delling; K Winkler; G Landbeck
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.

Authors:  Paul A Meyers; John H Healey; Alexander J Chou; Leonard H Wexler; Pamela R Merola; Carol D Morris; Michael P Laquaglia; Michael G Kellick; Sara J Abramson; Richard Gorlick
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

Review 5.  Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.

Authors:  Robert S Benjamin
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

7.  A retrospective review of the frequency and nature of acute hypersensitivity reactions at a medium-sized infusion center: comparison to reported values and inconsistencies found in literature.

Authors:  Patricia A Demoor; Yuri Matusov; Colleen Kelly; Shobha Kolan; Linda Barnachea; Lyudmila A Bazhenova
Journal:  J Cancer       Date:  2011-03-10       Impact factor: 4.207

8.  STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma.

Authors:  Toru Oi; Kunihiro Asanuma; Akihiko Matsumine; Takao Matsubara; Tomoki Nakamura; Takahiro Iino; Yumiko Asanuma; Mikinobu Goto; Kazuma Okuno; Takuya Kakimoto; Yuki Yada; Akihiro Sudo
Journal:  Int J Oncol       Date:  2016-11-03       Impact factor: 5.650
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.